Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Axsome Therapeutics (AXSM) posted Q2 Auvelity sales of $180.3 million, up 51% year over year, as the drug moves beyond major depressive disorder into Alzheimer's agitation treatment.

The expansion is already showing up in prescribing data. New patient starts among seniors jumped 126% following the launch, a figure that points to early traction in the older demographic that defines the Alzheimer's population. That is interpretation, not a reported causal link, but the timing is notable.

The company is projecting Auvelity could eventually reach $8 billion in annual peak sales. That target sits against a current quarterly run rate of $180.3 million, which annualizes to roughly $721 million (our arithmetic, not a company figure). The gap between those two numbers is the core of the bull case: it requires sustained growth well beyond the current 51% pace and successful penetration of the Alzheimer's agitation market.

Beyond Auvelity, the thesis rests on additional commercial products and pipeline candidates that could reshape AXSM into a major neuroscience pharmaceutical company by 2030. No specific pipeline timelines or sales figures accompany that claim, so treat it as long-dated optionality rather than a near-term driver.